Key facts
- It has raised $29.8M; the latest was Later Stage VC ($17.5M) in Jul 2025.
- Notable investors include Endeavor Italy, B-Yond Ventures, Bruno Farmaceutici, DayOne Accelerator, Deep Ocean Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for InSilicoTrials
- ·The full record, as it builds
Funding rounds
No funding rounds for InSilicoTrials are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InSilicoTrials
Operator of a cloud-based scientific innovation platform intended to accelerate drug development. The company offers computational models and artificial intelligence technology to analyze large amounts of data and predict the safety and efficacy of potential drug compounds, enabling pharmaceutical, biotech, and researchers to cut research costs, reduce and replace animal testing and clinical trials, and improve the safety of new medical products.
- Sector
- Healthcare
- HQ
- Trieste, Italy
- Founded
- 2017
- Employees
- 29
- Website
- insilicotrials.com/
- Ownership
- Privately Held (backing)
InSilicoTrials doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InSilicoTrials shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InSilicoTrials in its N-PORT filings yet. We sweep new filings monthly.